The Viveve System is now cleared for marketing in 47 countries throughout the world.

"U.A.E. and Lebanon represent very important markets for Viveve and the regulatory approvals of the Viveve System in these countries are significant developments. In partnership with our distribution partner, Medica Group, we have begun the commercialization efforts for the Viveve System in the Middle East to make this clinically-proven treatment available to women in the region whose quality of life is impacted by vaginal laxity," said Patricia Scheller, chief executive officer of Viveve.

Viveve Medical, Inc. is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life.

The company's lead product, the internationally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity that can result in decreased physical sensation and sexual satisfaction.

Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks.

The Viveve System uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office.